Hepatocellular carcinoma (HCC) represents the most common malignancy in Egypt and worldwide. However, non -invasive diagnostic/prognostic biomarkers for early HCC detection are still missing. Circular RNAS (CIRCRNAS) is one of the promising biomarkers. They are considered constant, long -term non -coded RNA in a sealed circular form held by covalent bonds. Circrnas have been observed in several genetic studies to play a vital role in the onset and evolution of malignancy. Our current cross -sectional study aimed to evaluate the possible role of HSA_CIRC_101555 as a diagnostic biomarker for HCC, in addition to comparing its prediction and predicting reaction to treatment.
Method
The level of expression of the serum of HSA_CIRC_101555 was measured using a chain reaction in real -time polymerase in 62 clinical/radiologically diagnosed Egyptian patients with HCC at the onset and three months after treatment with HCC. These results were compared to those of 30 healthy issues.
Results
Our data showed that the average CIRCRNA value was higher in cases of HCC (7.66 ± 3.74) compared to healthy witnesses (1.21 ± 0.96). In addition, the CIRCRNA value showed excellent diagnostic accuracy in differentiation of patients with HCC from healthy witnesses to a cutting point of 1,966, as indicated by an area below the 0.984 curve. In addition, it has shown a predictive role in the differentiation between the development of HCC and the regression in these patients based on the MRECIST response criteria at 5,1150, with an area below the 0.891 curve and a standard error of 0.058. Interestingly, the positive correlations between Circrna levels after intervention and laboratory measurements were observed in patients with HCC, including the albumin-diluubin rating (R = 0.424, P. = 0.001 **); P. = 0.001 **), alpha-fetoprotein (r = 0.273, P. = 0.032*), the ratio of aspartic aminotransferase/alanine aminotransferase (r = 0.284, P. = 0.025*), fibrosis-4 (r = 0.501, P. = 0.000 **) and aspartic aminotransferase in platelet rating (r = 0.436, P. = 0.000 **), indicating a correlation with the worsening of inflammation of the liver, fibrosis and progression of the disease. Finally, CIRCRNA prices after intervention were significantly associated with clinical/pathological characteristics of tumor keys, including larger tumors (> 5 cm) (P. = 0.019), multiplicity (volume numbers> 3) (P. = 0.031), vascular invasion (P. = 0.030), Barcelona Clinic of Liver Cancer Stage C (P. = 0.007) and advanced Tomur, Node, Metastasis Stage (P. = 0.012).
Conclusions
From our own knowledge, this is the first study that highlights HSA_CIRC_101555 expression levels in Egyptian patients with HCC. Our data showed the arrangement upward in HCC cases compared to healthy people. In addition, its increased levels were associated with the evolution of the volume according to the RECIST/MRECIST categories. In addition, the significant association with the indicators/scores of liver inflammation, malfunction and pathological characteristics of the tumor highlights its potential as a promising diagnostic/predictive biological index, helping to better clinical decision -making for managing hepatocellular carcinoma.
Source:
Magazine report:
Gado, ms, et al. (2025). The potential oncogenic role of the serum -derived HSA_CIRC_101555 as a non -invasive diagnostic/predictive index in patients with hepatocellular carcinoma. Gene expression. Doi.org/10.14218/ge.2025.00012.
